The exomes of the NCI-60 panel: A genomic resource for cancer biology and systems pharmacology

Ogan D. Abaan; Eric C. Polley; Sean R. Davis; Yuelin J. Zhu; Sven Bilke; Robert L. Walker; Marbin Pineda; Yevgeniy Gindin; Yuan Jiang; William C. Reinhold; Susan L. Holbeck; Richard M. Simon; James H. Doroshow; Yves Pommier; Paul S. Meltzer

doi:10.1158/0008-5472.CAN-12-3342

The exomes of the NCI-60 panel: A genomic resource for cancer biology and systems pharmacology

Ogan D. Abaan, Eric C. Polley, Sean R. Davis, Yuelin J. Zhu, Sven Bilke, Robert L. Walker, Marbin Pineda, Yevgeniy Gindin, Yuan Jiang, William C. Reinhold, Susan L. Holbeck, Richard M. Simon, James H. Doroshow, Yves Pommier, Paul S. Meltzer

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

196 Scopus citations

Abstract

The NCI-60 cell lines are the most frequently studied human tumor cell lines in cancer research. This panel has generated the most extensive cancer pharmacology database worldwide. In addition, these cell lines have been intensely investigated, providing a unique platform for hypothesis-driven research focused on enhancing our understanding of tumor biology. Here, we report a comprehensive analysis of coding variants in the NCI-60 panel of cell lines identified by whole exome sequencing, providing a list of possible cancer specific variants for the community. Furthermore, we identify pharmacogenomic correlations between specific variants in genes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib, and bleomycin showing one of many ways the data could be used to validate and generate novel hypotheses for further investigation. As new cancer genes are identified through large-scale sequencing studies, the data presented here for the NCI-60 will be an invaluable resource for identifying cell lines with mutations in such genes for hypothesisdriven research. To enhance the utility of the data for the greater research community, the genomic variants are freely available in different formats and from multiple sources including the CellMiner and Ingenuity websites.

Original language	English (US)
Pages (from-to)	4372-4382
Number of pages	11
Journal	Cancer research
Volume	73
Issue number	14
DOIs	https://doi.org/10.1158/0008-5472.CAN-12-3342
State	Published - Jul 15 2013

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/0008-5472.CAN-12-3342

Cite this

Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J., Bilke, S., Walker, R. L., Pineda, M., Gindin, Y., Jiang, Y., Reinhold, W. C., Holbeck, S. L., Simon, R. M., Doroshow, J. H., Pommier, Y., & Meltzer, P. S. (2013). The exomes of the NCI-60 panel: A genomic resource for cancer biology and systems pharmacology. Cancer research, 73(14), 4372-4382. https://doi.org/10.1158/0008-5472.CAN-12-3342

Abaan, OD, Polley, EC, Davis, SR, Zhu, YJ, Bilke, S, Walker, RL, Pineda, M, Gindin, Y, Jiang, Y, Reinhold, WC, Holbeck, SL, Simon, RM, Doroshow, JH, Pommier, Y & Meltzer, PS 2013, 'The exomes of the NCI-60 panel: A genomic resource for cancer biology and systems pharmacology', Cancer research, vol. 73, no. 14, pp. 4372-4382. https://doi.org/10.1158/0008-5472.CAN-12-3342

@article{0cc06e1f06a24f7eb6fefb688fc57b41,

title = "The exomes of the NCI-60 panel: A genomic resource for cancer biology and systems pharmacology",

abstract = "The NCI-60 cell lines are the most frequently studied human tumor cell lines in cancer research. This panel has generated the most extensive cancer pharmacology database worldwide. In addition, these cell lines have been intensely investigated, providing a unique platform for hypothesis-driven research focused on enhancing our understanding of tumor biology. Here, we report a comprehensive analysis of coding variants in the NCI-60 panel of cell lines identified by whole exome sequencing, providing a list of possible cancer specific variants for the community. Furthermore, we identify pharmacogenomic correlations between specific variants in genes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib, and bleomycin showing one of many ways the data could be used to validate and generate novel hypotheses for further investigation. As new cancer genes are identified through large-scale sequencing studies, the data presented here for the NCI-60 will be an invaluable resource for identifying cell lines with mutations in such genes for hypothesisdriven research. To enhance the utility of the data for the greater research community, the genomic variants are freely available in different formats and from multiple sources including the CellMiner and Ingenuity websites.",

author = "Abaan, {Ogan D.} and Polley, {Eric C.} and Davis, {Sean R.} and Zhu, {Yuelin J.} and Sven Bilke and Walker, {Robert L.} and Marbin Pineda and Yevgeniy Gindin and Yuan Jiang and Reinhold, {William C.} and Holbeck, {Susan L.} and Simon, {Richard M.} and Doroshow, {James H.} and Yves Pommier and Meltzer, {Paul S.}",

year = "2013",

month = jul,

day = "15",

doi = "10.1158/0008-5472.CAN-12-3342",

language = "English (US)",

volume = "73",

pages = "4372--4382",

journal = "Cancer research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "14",

}

TY - JOUR

T1 - The exomes of the NCI-60 panel

T2 - A genomic resource for cancer biology and systems pharmacology

AU - Abaan, Ogan D.

AU - Polley, Eric C.

AU - Davis, Sean R.

AU - Zhu, Yuelin J.

AU - Bilke, Sven

AU - Walker, Robert L.

AU - Pineda, Marbin

AU - Gindin, Yevgeniy

AU - Jiang, Yuan

AU - Reinhold, William C.

AU - Holbeck, Susan L.

AU - Simon, Richard M.

AU - Doroshow, James H.

AU - Pommier, Yves

AU - Meltzer, Paul S.

PY - 2013/7/15

Y1 - 2013/7/15

N2 - The NCI-60 cell lines are the most frequently studied human tumor cell lines in cancer research. This panel has generated the most extensive cancer pharmacology database worldwide. In addition, these cell lines have been intensely investigated, providing a unique platform for hypothesis-driven research focused on enhancing our understanding of tumor biology. Here, we report a comprehensive analysis of coding variants in the NCI-60 panel of cell lines identified by whole exome sequencing, providing a list of possible cancer specific variants for the community. Furthermore, we identify pharmacogenomic correlations between specific variants in genes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib, and bleomycin showing one of many ways the data could be used to validate and generate novel hypotheses for further investigation. As new cancer genes are identified through large-scale sequencing studies, the data presented here for the NCI-60 will be an invaluable resource for identifying cell lines with mutations in such genes for hypothesisdriven research. To enhance the utility of the data for the greater research community, the genomic variants are freely available in different formats and from multiple sources including the CellMiner and Ingenuity websites.

AB - The NCI-60 cell lines are the most frequently studied human tumor cell lines in cancer research. This panel has generated the most extensive cancer pharmacology database worldwide. In addition, these cell lines have been intensely investigated, providing a unique platform for hypothesis-driven research focused on enhancing our understanding of tumor biology. Here, we report a comprehensive analysis of coding variants in the NCI-60 panel of cell lines identified by whole exome sequencing, providing a list of possible cancer specific variants for the community. Furthermore, we identify pharmacogenomic correlations between specific variants in genes such as TP53, BRAF, ERBBs, and ATAD5 and anticancer agents such as nutlin, vemurafenib, erlotinib, and bleomycin showing one of many ways the data could be used to validate and generate novel hypotheses for further investigation. As new cancer genes are identified through large-scale sequencing studies, the data presented here for the NCI-60 will be an invaluable resource for identifying cell lines with mutations in such genes for hypothesisdriven research. To enhance the utility of the data for the greater research community, the genomic variants are freely available in different formats and from multiple sources including the CellMiner and Ingenuity websites.

UR - http://www.scopus.com/inward/record.url?scp=84880861468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880861468&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-3342

DO - 10.1158/0008-5472.CAN-12-3342

M3 - Article

C2 - 23856246

AN - SCOPUS:84880861468

SN - 0008-5472

VL - 73

SP - 4372

EP - 4382

JO - Cancer research

JF - Cancer research

IS - 14

ER -

The exomes of the NCI-60 panel: A genomic resource for cancer biology and systems pharmacology

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this